Wolf Popper LLP Investigates Claims That the Proposed Acquisition of Salix Pharmaceuticals, Ltd. May Not Be In the Best Interests of Its Investors
NEW YORK, Feb. 23, 2015 /PRNewswire/ -- Wolf Popper LLP is investigating claims on behalf of investors in Salix Pharmaceuticals, Ltd. ("Salix") (Nasdaq: SLXP), concerning the proposed acquisition of Salix by Valeant Pharmaceuticals International, Inc. ("NYSE: VRX"). Salix shareholders seeking more information about this acquisition are advised to contact Carl Stine at (212) 759-4600 or [email protected].
The investigation concerns whether Salix's directors are breaching their fiduciary duties by failing to adequately maximize shareholder value. Under the terms of the proposed transaction, Salix's shareholders will receive $158.00 per share in cash for each Salix share they own. The proposed transaction is valued at approximately $14.5 billion. However, the offer price is just a mere $0.15 per share or 0.1% premium to Salix's closing price on February 21, 2015 of $157.85 per share and below Salix's 52-week high price of $169.17 per share.
Wolf Popper LLP has extensive experience representing investors in mergers and acquisition lawsuits and has successfully ensured that investors receive the maximum compensation. Twelve Wolf Popper attorneys were named Rising Stars or Super Lawyers in the 2014 Super Lawyers New York City Metro Edition, including Wolf Popper partner Carl Stine, who was included in the Super Lawyers Top 100 List for the New York City Metro area. View Wolf Popper attorney biographies at www.wolfpopper.com.
Attorney Advertising: Prior Results Do Not Guarantee A Similar Outcome.
Wolf Popper LLP
845 Third Avenue
New York, New York 10022
Telephone: 212-759-4600
Toll Free Tel: 877-370-7703
Toll Free Fax: 877-370-7704
Email: [email protected]
SOURCE Wolf Popper LLP
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article